<DOC>
	<DOCNO>NCT01245088</DOCNO>
	<brief_summary>Pilot trial open-label chondroitin sulfate 400 mg TID adult patient mild moderate Crohn 's disease . Primary endpoint evidence bilogic effect assess serum tissue cytokine analysis . Secondary endpoint evidence clinical effect , endoscopic healing , histologic improvment . Trial duration 8 week .</brief_summary>
	<brief_title>Chondroitin Sulfate Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Colonic ileocolonic CD diagnose least 3 month . 2 . Active CD , define Crohn 's Disease Activity Index ( CDAI ; Appendix A ) [ Best 1976 ] great 200 less 320 time entry study . 3 . Age &gt; 18 year . 4 . Patients receive oral topical 5aminosalicylates must stable dose four week prior enrollment . 5 . Patients azathioprine , 6mercaptopurine , methotrexate must stable dos 14 week prior enrollment . 6 . Patients corticosteroid must stable dos 2 week prior enrollment . 7 . Patients receive corticosteroid enema must stable dose 3 week prior enrollment . 8 . Patient biologic therapy infliximab , adalimumab , certolizumab must stable therapy 12 week prior enrollment 9 . Patient must sign informed consent . 1 . Patients small bowel CD , fistulizing CD , gastroduodenal CD without colonic involvement . 2 . Patients know ulcerative colitis . 3 . Patients expect require surgery within 30 day complication CD . 4 . Patients CD intraabdominal abscess . 5 . Patients require continuous antibiotic ; antibiotic may take point enrollment study . 6 . Patients severe cardiac , pulmonary , renal disease . 7 . Patients h/o malignancy resect basal cell carcinoma skin 8 . Patients participate another clinical research study past 8 week . 9 . Patients pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>chondroitin sulfate</keyword>
</DOC>